Download pdf
Antiviral research and detecting viral nucleic acids based on the CRISPR-Cas technology
- 1 University of Science and Technology of China
* Author to whom correspondence should be addressed.
Abstract
Viruses constructed from nucleic acids, either deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), are encased in a protein covering and require a living cell to reproduce. Symptoms of viral infections can range from asymptomatic to severe illness, and their impact has become increasingly apparent in recent years. For instance, globally, the Corona Virus Disease 2019 (COVID-19) epidemic alone has resulted in millions of infections and millions of fatalities. Consequently, the development of effective tools for antiviral resistance is an urgent need. Early detection of viral infections can be achieved through nucleic acid detection, while gene editing techniques offer a promising solution for treating and counteracting the harmful effects of viruses, thereby minimizing economic and property loss. The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and associated (CRISPR-associated, Cas) protein system (CRISPR-Cas) is an emerging gene editing tool that has demonstrated remarkable accuracy and efficiency with its rapidly expanding applications. This review delves into the principles and applications of Cas12a, Cas13, and other systems in nucleic acid detection, highlighting the significant contributions of Cas9, Cas12a, Cas13, and other systems in establishing resistance against DNA and/or RNA viral infections, and outlines the strengths and limitations of the CRISPR-Cas system in current applications. Precautions and suggestions for the system’s safe application are also presented, with an optimistic outlook for its prospects.
Keywords
CRISPR-Cas, virus, viral nucleic acid detection
[1]. Snell L M, McGaha T L and Brooks D G 2017 Type I interferon in chronic virus infection and cancer Trends Immunol. 38(8) 542-57
[2]. Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S and Horvath P 2007 CRISPR provides acquired resistance against viruses in prokaryotes Science 315(5819) 1709-12
[3]. McGinn J and Marraffini L A 2019 Molecular mechanisms of CRISPR-Cas spacer acquisition Nat. Rev. Microbiol. 17(1) 7-12
[4]. Schindele P, Wolter F and Puchta H 2018 Transforming plant biology and breeding with CRISPR/Cas9 Cas12 and Cas13 FEBS Lett. 592(12) 1954-67
[5]. Zhang T, Zheng Q, Yi X, An H, Zhao Y, Ma S and Zhou G 2018 Establishing RNA virus resistance in plants by harnessing CRISPR immune system Plant Biotechnol. J. 16(8) 1415-23
[6]. Chen J S 2021 CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity (vol 371 eabh0317 2021) Science 371(6531) 791
[7]. Kellner M J, Koob J G, Gootenberg J S, Abudayyeh O O and Zhang F 2019 SHERLOCK: nucleic acid detection with CRISPR nucleases Nat. Protoc. 14(10) 2986-3012
[8]. Li S Y, Cheng Q X, Wang J M, Li X Y, Zhang Z L, Gao S and Wang J 2018 CRISPR-Cas12a-assisted nucleic acid detection Cell Discovery 4(1) 20
[9]. Broughton J P, Deng X, Yu G, Fasching C L, Servellita V, Singh J and Chiu C Y 2020 CRISPR–Cas12-based detection of SARS-CoV-2 Nat. Biotechnol. 38(7) 870-4
[10]. Gootenberg J S, Abudayyeh O O, Lee J W, Essletzbichler P, Dy A J, Joung J and Zhang F 2017 Nucleic acid detection with CRISPR-Cas13a/C2c2 Science 356(6336) 438-42
[11]. Broughton J P, Deng X, Yu G, Fasching C L, Servellita V, Singh J and Chiu C Y 2020 CRISPR-Cas12-based detection of SARS-CoV-2 Nat. Biotechnol. 38(7) 870-4
[12]. Ramachandran A and Santiago J G 2021 CRISPR enzyme kinetics for molecular diagnostics Anal. Chem. 93(20) 7456-64
[13]. Kaminski M M, Abudayyeh O O, Gootenberg J S, Zhang F and Collins J J 2021 CRISPR-based diagnostics Nat. Biomed. Eng. 5(7) 643-56
[14]. Cho S W, Kim S, Kim Y, Kweon J, Kim H S, Bae S and Kim J S 2014 Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases Genome Res. 24(1) 132-41
[15]. Kennedy E M, Kornepati A V, Goldstein M, Bogerd H P, Poling B C, Whisnant A W and Cullen B R 2014 Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease J. Virol. 88(20) 11965-72
[16]. Aman R, Ali Z, Butt H, Mahas A, Aljedaani F, Khan M Z and Mahfouz M 2018 RNA virus interference via CRISPR/Cas13a system in plants Genome Biol. 19(1) 1-9
[17]. Chandrasekaran J, Brumin M, Wolf D, Leibman D, Klap C, Pearlsman M and Gal‐On A 2016 Development of broad virus resistance in non‐transgenic cucumber using CRISPR/Cas9 technology Mol. Plant Pathol. 17(7) 1140-53
[18]. Lin S R, Yang H C, Kuo Y T, Liu C J, Yang T Y, Sung K C and Chen P J 2014 The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo Mol. Ther.-Nucleic Acids 3
[19]. Roehm P C, Shekarabi M, Wollebo H S, Bellizzi A, He L, Salkind J and Khalili K 2016 Inhibition of HSV-1 replication by gene editing strategy Sci. Rep. 6(1) 23146
[20]. Ebina H, Misawa N, Kanemura Y and Koyanagi Y 2013 Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus Sci. Rep. 3(1) 2510
[21]. Hou P, Chen S, Wang S, Yu X, Chen Y, Jiang M and Guo D 2015 Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection Sci. Rep. 5(1) 15577
[22]. Price A A, Sampson T R, Ratner H K, Grakoui A and Weiss D S 2015 Cas9-mediated targeting of viral RNA in eukaryotic cells Proceedings of the Natl. Acad. Sci. 112(19) 6164-9
Cite this article
Li,P. (2023). Antiviral research and detecting viral nucleic acids based on the CRISPR-Cas technology. Theoretical and Natural Science,27,107-113.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 2nd International Conference on Modern Medicine and Global Health
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).